Paradoxical adverse drug reactions: descriptive analysis of French reports

Abstract

Introduction

Paradoxical adverse drug reactions (ADRs) are defined as being opposing reactions to the pharmacological effect of drugs in relation to its pharmacodynamic properties. Their diagnosis is difficult as they are relatively rare with atypical clinical presentation (with the possibility of being confused with drug ineffectiveness or the worsening of the underlying disease). This kind of ADR may be particularly subject to under-notification. The aim of the present study is to describe paradoxical ADRs using the French PharmacoVigilance DataBase (FPVDB).

Method

We analysed all reports recorded in the FPVDB with drugs defined as “suspect” and which included the term “paradoxical reaction” (PR) (according to MedDRA classification) from 01/01/1984 to 12/31/2018. The drugs were classified according to the Chemical Therapeutic Anatomical Classification (ATC).

Results

We found 57 reports of PR, with half of them recorded between 2015 and 2018. The median age of patients was 46 years, mainly male (54%). The most frequently involved drugs were immunomodulating agents (n = 28, 49%) and psychotropics (n = 28, 49%). The leading paradoxical ADRs were psychiatric (anxiety, sleep and behavioural disorders) and skin-related. In 19 cases (33%), PR was related to benzodiazepines mainly occurring in patients in extreme ages (five cases in children and patients > 70, respectively, 53%). For psychotropic-induced PR (n = 28), known contributory factors (alcohol consumption, underlying psychiatric diseases) were found in 18 cases (64%). Paradoxical reactions with immunomodulating agents were mainly related to skin ADRs (n = 25). For psychotropics, paradoxical ADRs occurred rapidly after a mean delay of 1 day, predominantly following high doses. We also identified several “unexpected” paradoxical reactions, such as cognitive degradation with donepezil, or a return to impulsive smoking addiction with varenicline.

Conclusion

This study highlights that pharmacovigilance databases like the French database make it possible to investigate the main characteristics of paradoxical reactions to drugs. This ADR was mainly found in the FPVDB with psychotropic drugs and immunomodulating agents. Moreover, pharmacovigilance databases enable the identification of some signs of “unexpected paradoxical reactions”. In order to identify this type of ADR more effectively, work on awareness and harmonization is required to register these reports. The addition of the term “paradoxical reaction to the drug” to the list of other symptoms would facilitate their identification and analysis.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Smith SW, Hauben M, Aronson JK (2012) Paradoxical and bidirectional drug effects. Drug Saf 35:173–189

    CAS  PubMed  Google Scholar 

  2. 2.

    Hauben M, Aronson JK (2006) Paradoxical reactions: under recognized adverse effects of drugs? Drug Saf 29:911–1010

    Google Scholar 

  3. 3.

    Moore N, Berdai D, Blin P, Droz C (2019) Pharmacovigilance the next chapter. Therapie 74:557–567

    Article  Google Scholar 

  4. 4.

    Introductory guide MedDRA. https://www.meddra.org/sites/default/files/guidance/file/000354_intguide_22.1.pdf. Accessed 28/10/2019

  5. 5.

    Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259

    CAS  Article  Google Scholar 

  6. 6.

    Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B (2016) Imputabilité en pharmacovigilance: de la méthode française originelle aux méthodes réactualisées. Therapie 71:171–178

    Article  Google Scholar 

  7. 7.

    ATC Structure and principles. https://www.whocc.no/atc/structure_and_principles. Accessed 28/10/2019

  8. 8.

    Figueras A, Pedrós C, Valsecia M, Laporte JR (2002) Therapeutic ineffectiveness: heads or tails? Drug Saf 25:485–487

    Article  Google Scholar 

  9. 9.

    Gutierez MM, Roper J, Pockhee H (2001) Paradoxical reactions to benzodiazepines: when to expect the unexpected. Am J Nurs 101:34–39

    Article  Google Scholar 

  10. 10.

    Weinbroum AA, Szold O, Ogorek D, Flasishon R (2001) The midazolam-induced paradox phenomenon is reversible by flumazenil: epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol 18:789–797

    CAS  Article  Google Scholar 

  11. 11.

    Hall RW, Zisook S (1981) Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 11:99–104

    Article  Google Scholar 

  12. 12.

    Davies CJ, Davies DM (2001) Paradoxical reactions to commonly used drugs. Adverse Drug React Bull 207:807–810

    Article  Google Scholar 

  13. 13.

    McKenzie WS, Rosenberg M (2010) Paradoxical reaction following administration of a benzodiazepine. J Oral Maxillofac Surg 68:3034–3036

    Article  Google Scholar 

  14. 14.

    Mancuso E, Tanzi G, Gabay M (2004) Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy 24:1177–1185

    CAS  Article  Google Scholar 

  15. 15.

    Fiorino G, Danese S, Pariente B, Allez M (2014) Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 13:15–19

    CAS  Article  Google Scholar 

  16. 16.

    Joyau C, Veyrac G, Dixneuf V, Jolliet P (2012) Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 30:700–706

    PubMed  Google Scholar 

  17. 17.

    Del Giorno R, Iodice A, Mangas C, Gabutti L (2019) New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Ther Adv Musculoskelet Dis 11:1–6

    Google Scholar 

  18. 18.

    Dika E, Varotti C, Bardazzi F, Maibach HI (2006) Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 25:1–11

    CAS  Article  Google Scholar 

  19. 19.

    Hsu C, Lin C, Lu L, Hu L (2015) Risperidone exacerbates psychosis: a paradoxical phenomenon? Aust N Z J Psychiatry 49:669–670

    Article  Google Scholar 

  20. 20.

    Fonda G, MacGregorb A, Ducasseb D, Brittnerba M (2014) Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. Psychiatry Res 216:286–287

    Article  Google Scholar 

  21. 21.

    Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152:174–180

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Yan Hakimi collected, analysed data in the French Pharmacovigilance database and contributed to the drafting of the paper. Nadine Petitpain and Véronique Pinzani contributed to the collection of the French Pharmacovigilance database. Jean Louis Montastruc reviewed the paper. Haleh Bagheri coordinated the entire of study and the drafting of the paper.

Corresponding author

Correspondence to Haleh Bagheri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 36 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hakimi, Y., Petitpain, N., Pinzani, V. et al. Paradoxical adverse drug reactions: descriptive analysis of French reports. Eur J Clin Pharmacol 76, 1169–1174 (2020). https://doi.org/10.1007/s00228-020-02892-2

Download citation

Keywords

  • Paradoxical adverse drug reactions
  • Pharmacovigilance
  • Drug safety
  • Benzodiazepines
  • Immunomodulating agents